



**Department of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting Agenda**

April 7th, 2015 6:00 – 8:30 p.m.

- | | |
|--|--------------------|
| 1. Executive Session | 6:00 - 6:30 |
| 2. Introductions and Approval of DUR Board Minutes
(Public Comment Prior to Board Action) | 6:30 - 6:40 |
| 3. DVHA Pharmacy Administration Updates <ul style="list-style-type: none">▪ Updates | 6:40 - 6:50 |
| 4. Medical Director Update <ul style="list-style-type: none">▪ Clinical Programs Update▪ Prescriber Comments | 6:50 – 7:00 |
| 5. Follow-up Items from Previous Meetings <ul style="list-style-type: none">▪ None at this time | 7:00 - 7:00 |
| 6. RetroDUR/DUR <ul style="list-style-type: none">▪ High dose/Long term use in individual patients on diazepam▪ Amiodarone DDI | 7:00 – 7:20 |
| 7. Clinical Update: Drug Reviews
(Public comment prior to Board action) | 7:20 – 7:30 |
| Abbreviated New Drug Reviews <ul style="list-style-type: none">▪ None at this time | |
| Full New Drug Reviews <ul style="list-style-type: none">▪ Bunavail® (buprenorphine HCl & naloxone HCl dihydrate)▪ Zubsolv® (buprenorphine & naloxone) | |
| 8. Therapeutic Drug Classes – Periodic Review
(Public comment prior to Board action) <ul style="list-style-type: none">▪ Anti-migraines▪ Antivirals, Topical▪ GI Ulcer Therapies▪ Fibromyalgia Agents▪ Leukotriene Modifiers▪ Gaucher Disease | 7:30 – 8:00 |
| 9. New Managed Therapeutic Drug Classes
(Public comment prior to Board action) <ul style="list-style-type: none">▪ None at this time | 8:00 – 8:00 |
| 10. Review of Newly-Developed/Revised
Clinical Coverage Criteria and/or Preferred Products
(Public comment prior to Board action) | 8:00 – 8:00 |

- None at this time

11. General Announcements Selected FDA Safety Alerts

8:00– 8:30

FDA Drug Safety Communication: FDA requires label warnings to prohibit sharing of multi-dose diabetes pen devices among patients

http://www.fda.gov/Drugs/DrugSafety/ucm435271.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Testosterone Products: Drug Safety Communication - FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack And Stroke

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm436280.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Chantix (varenicline): Drug Safety Communication - FDA Updates Label to Include Potential Alcohol Interaction

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm437415.htm>

FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni or Sovaldi) in combination with another Direct Acting Antiviral drug

http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Zyprexa Relprevv (olanzapine pamoate): Drug Safety Communication- FDA Review of Study Sheds Light on Two Deaths Associated with the Injectable Schizophrenia Drug

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm439472.htm>

Nationwide Alert: DEA Calls Opioid a Serious Public Health Threat

12. Adjourn

8:30